NovaBridge Biosciences announces the appointment of Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board for its subsidiary Visara, Inc. The appointments highlight the potential of VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, which is expected to be Phase-3-ready in 2026. Dr. Rich and Dr. Quezada-Ruiz bring extensive expertise in ophthalmology and drug development, signaling a strong commitment to advancing cutting-edge treatments for wet AMD, DME, and RVO. This strategic move underscores NovaBridge’s dedication to assembling a world-class team in the field.

Read more at GlobeNewswire: NovaBridge’s Visara Subsidiary Appoints Distinguished